Indivior Pharmaceuticals — Key Risks

Extreme Revenue Concentration in a Single Product, SUBLOCADE

SUBLOCADE, a once-monthly injectable for opioid use disorder, accounted for 69% of total net revenues in 2025, up from 58% in 2023. This means the company's financial health is tightly tied to one product's performance. A new competitor (BRIXADI) already launched in the U.S. in 2023, and any generic challenge, pricing pressure, or coverage restriction on SUBLOCADE could severely damage the business.

A Long History of Costly Legal Battles That Is Far From Over

Indivior has settled over $1.3 billion in antitrust, fraud, and opioid-related cases in recent years, including a $600 million DOJ resolution in 2020 and a $385 million antitrust class settlement in 2023. New lawsuits are now piling up claiming SUBOXONE Film caused dental injuries, with class actions filed in multiple U.S. courts and in Canada. The company remains under FTC and state attorney general oversight orders through 2030, with criminal contempt exposure if it violates them.

Medicaid Dependence Makes Congressional Budget Cuts a Direct Threat

OUD patients are disproportionately covered by Medicaid, making Indivior unusually sensitive to government healthcare spending. The filing specifically calls out the 2025 budget reconciliation act as a potential source of Medicaid cuts that could reduce patient eligibility or restrict coverage of higher-cost treatments like SUBLOCADE. Unlike companies with commercially insured patient bases, Indivior has limited ability to shift its revenue mix away from government programs.

Sole-Source Manufacturing Creates a Supply Chain With Little Margin for Error

Indivior relies almost entirely on third-party manufacturers, and most products — including the critical active ingredient buprenorphine — have only a single or dual source of supply. If a manufacturing partner fails, finding and qualifying a replacement takes an average of 36 months. SUBLOCADE is a complex injectable that is particularly difficult to manufacture, amplifying the consequences of any disruption.

Ongoing Government Pricing Oversight Limits Ability to Respond to Cost Pressures

The company is bound by detailed pricing and reporting obligations under Medicaid rebate programs, the 340B drug pricing program, and the FTC Stipulated Order. Errors in calculating these rebates can trigger penalties, and the company is currently defending a federal False Claims Act lawsuit alleging it submitted incorrect pricing data. The filing notes that its accrued rebate liability stood at $582 million at year-end 2025, exceeding current assets by over $250 million.

A Leveraged Balance Sheet With Tight Debt Covenants Reduces Financial Flexibility

Indivior carries a term loan with an unpaid balance of $333 million, governed by covenants that require the company to maintain specific ratios of debt-to-earnings and earnings-to-interest. If revenue falls, these ratios could be breached. The covenants also restrict dividends, share buybacks, and acquisitions — limiting management's options precisely when financial flexibility would matter most.

Pipeline Candidates Are Still Early-Stage With Uncertain Outcomes

The two lead pipeline products, INDV-6001 (a new buprenorphine injectable) and INDV-2000 (a novel addiction treatment targeting the orexin system), only recently completed Phase 1 and Phase 2 studies, with results expected in early 2026. A prior pipeline bet — the $146 million acquisition of Opiant Pharmaceuticals in 2023 — was written off in 2025 when the company discontinued sales of its key product, OPVEE. Early-stage trials frequently fail to replicate in larger studies, and there is no guarantee either candidate will reach the market.